Lion TCR Pte. Ltd.   Report issue

For profit Phase 1 Phase 2
Founded: Singapore Singapore (2015)

Organization Overview

First Clinical Trial
2018
NCT04677088
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Lion TCR Pte. Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

lenvatinib (lenvima) (1 trial)

liocyx (2 trials)

Drugs in Phase 1 Trials (3)

mrna hbv/tcr t-cells (1 trial)

tcr redirected t cells (1 trial)

tcr-t cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 5